Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 416 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors April 30, 2021 K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF... March 11, 2026 Load more HOT NEWS Woman Donates 500 Care Packages To Breast Cancer Patients Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in... FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers...
